Walleye Trading’s C4 Therapeutics CCCC Stock Holding History

Walleye Trading’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-24,794	Closed	-$203K	–	4339
2024 Q1	$203K	Buy	+24,794	New	+$192K	﹤0.01%	3416

Other funds holding CCCC

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Walleye Trading's CCCC Position: Q2 2024 in Review

Walleye Trading sold out of C4 Therapeutics (CCCC) in Q2 2024, closing a stake of 24,794 shares — an estimated $203K sold.

Walleye Trading first reported a position in CCCC in Q1 2024 and held it in 1 quarter. The position peaked at $203K in Q1 2024. 115 funds tracked by Wall St. Rank hold CCCC as of Q2 2024.

Walleye Trading reported no remaining C4 Therapeutics position as of Q2 2024 after selling out during the quarter.
Walleye Trading sold 24,794 C4 Therapeutics shares in Q2 2024, an estimated $203K.
Walleye Trading first reported a position in C4 Therapeutics in Q1 2024 and held it in 1 quarter.
Walleye Trading's C4 Therapeutics position peaked at $203K in Q1 2024.
115 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2024.

Based on Walleye Trading's 13F filing for Q2 2024, filed 14 Aug 2024.